Precision oncology deeptech platform leveraging genomic instability biomarkers to personalize cancer treatment and de-risk drug development. Analyzes tumor biopsy and multimodal clinical data to stratify chemotherapy response into predicted responders, non-responders, and patients at risk of therapy-induced harm, delivering actionable insights for clinicians and drug developers.